These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 21288700)
21. Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles. Kuo YC; Lin PI; Wang CC Nanomedicine (Lond); 2011 Aug; 6(6):1011-26. PubMed ID: 21707298 [TBL] [Abstract][Full Text] [Related]
22. Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate. Cenni E; Granchi D; Avnet S; Fotia C; Salerno M; Micieli D; Sarpietro MG; Pignatello R; Castelli F; Baldini N Biomaterials; 2008 Apr; 29(10):1400-11. PubMed ID: 18191195 [TBL] [Abstract][Full Text] [Related]
23. Mixture designs in the optimisation of PLGA nanoparticles: influence of organic phase composition on β-aescin encapsulation. Ven HV; Vandervoort J; Weyenberg W; Apers S; Ludwig A J Microencapsul; 2012; 29(2):115-25. PubMed ID: 22047548 [TBL] [Abstract][Full Text] [Related]
24. Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality. McCarron PA; Marouf WM; Donnelly RF; Scott C J Biomed Mater Res A; 2008 Dec; 87(4):873-84. PubMed ID: 18228271 [TBL] [Abstract][Full Text] [Related]
25. PLGA nanoparticles loaded with the antileishmanial saponin β-aescin: factor influence study and in vitro efficacy evaluation. Van de Ven H; Vermeersch M; Matheeussen A; Vandervoort J; Weyenberg W; Apers S; Cos P; Maes L; Ludwig A Int J Pharm; 2011 Nov; 420(1):122-32. PubMed ID: 21864661 [TBL] [Abstract][Full Text] [Related]
26. Particle size control of poly(dl-lactide-co-glycolide) nanospheres for sterile applications. Tsukada Y; Hara K; Bando Y; Huang CC; Kousaka Y; Kawashima Y; Morishita R; Tsujimoto H Int J Pharm; 2009 Mar; 370(1-2):196-201. PubMed ID: 19100320 [TBL] [Abstract][Full Text] [Related]
27. Effect of microfluidization parameters on the physical properties of PEG-PLGA nanoparticles prepared using high pressure microfluidization. Sani SN; Das NG; Das SK J Microencapsul; 2009 Sep; 26(6):556-61. PubMed ID: 18946802 [TBL] [Abstract][Full Text] [Related]
28. Preparation and characterization of cationic chitosan-modified poly(D,L-lactide-co-glycolide) copolymer nanospheres as DNA carriers. Guan XP; Quan DP; Liao KR; Tao Wang ; Peng Xiang ; Mai KC J Biomater Appl; 2008 Jan; 22(4):353-71. PubMed ID: 17494965 [TBL] [Abstract][Full Text] [Related]
29. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin. Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176 [TBL] [Abstract][Full Text] [Related]
30. Cellular uptake of Poly-(D,L-lactide-co-glycolide) (PLGA) nanoparticles synthesized through solvent emulsion evaporation and nanoprecipitation method. Xiong S; Zhao X; Heng BC; Ng KW; Loo JS Biotechnol J; 2011 May; 6(5):501-8. PubMed ID: 21259442 [TBL] [Abstract][Full Text] [Related]
31. A novel technique for loading of paclitaxel-PLGA nanoparticles onto ePTFE vascular grafts. Lim HJ; Nam HY; Lee BH; Kim DJ; Ko JY; Park JS Biotechnol Prog; 2007; 23(3):693-7. PubMed ID: 17465527 [TBL] [Abstract][Full Text] [Related]
32. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells. Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655 [TBL] [Abstract][Full Text] [Related]
33. Intracellular drug delivery in Leishmania-infected macrophages: Evaluation of saponin-loaded PLGA nanoparticles. Van de Ven H; Vermeersch M; Vandenbroucke RE; Matheeussen A; Apers S; Weyenberg W; De Smedt SC; Cos P; Maes L; Ludwig A J Drug Target; 2012 Feb; 20(2):142-54. PubMed ID: 22080813 [TBL] [Abstract][Full Text] [Related]
34. Endocytosis-like uptake of surface-modified drug nanocarriers into giant unilamellar vesicles. Tahara K; Tadokoro S; Kawashima Y; Hirashima N Langmuir; 2012 May; 28(18):7114-8. PubMed ID: 22515197 [TBL] [Abstract][Full Text] [Related]
35. Preparation, characterization, and in vitro evaluation of physostigmine-loaded poly(ortho ester) and poly(ortho ester)/poly(D,L-lactide-co-glycolide) blend microspheres fabricated by spray drying. Wang L; Chaw CS; Yang YY; Moochhala SM; Zhao B; Ng S; Heller J Biomaterials; 2004 Jul; 25(16):3275-82. PubMed ID: 14980422 [TBL] [Abstract][Full Text] [Related]
36. Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles. Niu X; Zou W; Liu C; Zhang N; Fu C Drug Dev Ind Pharm; 2009 Nov; 35(11):1375-83. PubMed ID: 19832638 [TBL] [Abstract][Full Text] [Related]
37. Preparation of polyethyleneimine incorporated poly(D,L-lactide-co-glycolide) nanoparticles by spontaneous emulsion diffusion method for small interfering RNA delivery. Katas H; Cevher E; Alpar HO Int J Pharm; 2009 Mar; 369(1-2):144-54. PubMed ID: 19010405 [TBL] [Abstract][Full Text] [Related]
38. Nanomedical system for nucleic acid drugs created with the biodegradable nanoparticle platform. Yamamoto H; Tahara K; Kawashima Y J Microencapsul; 2012; 29(1):54-62. PubMed ID: 22034956 [TBL] [Abstract][Full Text] [Related]
39. The intracellular uptake ability of chitosan-coated Poly (D,L-lactide-co-glycolide) nanoparticles. Kim BS; Kim CS; Lee KM Arch Pharm Res; 2008 Aug; 31(8):1050-4. PubMed ID: 18787796 [TBL] [Abstract][Full Text] [Related]
40. Poly(D, L-lactide-co-glycolide) nanoparticles as delivery agents for photodynamic therapy: enhancing singlet oxygen release and photototoxicity by surface PEG coating. Boix-Garriga E; Acedo P; Casadó A; Villanueva A; Stockert JC; Cañete M; Mora M; Sagristá ML; Nonell S Nanotechnology; 2015 Sep; 26(36):365104. PubMed ID: 26293792 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]